These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31184298)

  • 1. Targeting Kinase Interaction Networks: A New Paradigm in PPI Based Design of Kinase Inhibitors.
    Jenardhanan P; Panneerselvam M; Mathur PP
    Curr Top Med Chem; 2019; 19(6):467-485. PubMed ID: 31184298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective.
    Carlino L; Rastelli G
    J Med Chem; 2016 Oct; 59(20):9305-9320. PubMed ID: 27559828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Profiling and Evaluation of Structure-based Kinase-Inhibitor Interactome in Cervical Cancer by Integrating In Silico Analyses and In Vitro Assays at Molecular and Cellular Levels.
    Zhu LX; Liu Q; Hua YF; Yang N; Zhang XG; Ding X
    Comput Biol Chem; 2019 Jun; 80():324-332. PubMed ID: 31078911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting protein-protein interactions as an anticancer strategy.
    Ivanov AA; Khuri FR; Fu H
    Trends Pharmacol Sci; 2013 Jul; 34(7):393-400. PubMed ID: 23725674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current compound coverage of the kinome.
    Hu Y; Furtmann N; Bajorath J
    J Med Chem; 2015 Jan; 58(1):30-40. PubMed ID: 25051177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising Targets in Anti-cancer Drug Development: Recent Updates.
    Kumar B; Singh S; Skvortsova I; Kumar V
    Curr Med Chem; 2017; 24(42):4729-4752. PubMed ID: 28393696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MAP kinase-interacting kinases--emerging targets against cancer.
    Diab S; Kumarasiri M; Yu M; Teo T; Proud C; Milne R; Wang S
    Chem Biol; 2014 Apr; 21(4):441-452. PubMed ID: 24613018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Kinase Modulators in Cellular Senescence for Use in Cancer Treatment.
    Lee CS; Baek J; Han SY
    Molecules; 2017 Aug; 22(9):. PubMed ID: 28841181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coumarins as anticancer agents: a review on synthetic strategies, mechanism of action and SAR studies.
    Thakur A; Singla R; Jaitak V
    Eur J Med Chem; 2015 Aug; 101():476-95. PubMed ID: 26188907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbazole Derivatives as Kinase-Targeting Inhibitors for Cancer Treatment.
    Ceramella J; Iacopetta D; Barbarossa A; Caruso A; Grande F; Bonomo MG; Mariconda A; Longo P; Carmela S; Sinicropi MS
    Mini Rev Med Chem; 2020; 20(6):444-465. PubMed ID: 31951166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence and utility of intrinsically disordered regions in kinases.
    Kathiriya JJ; Pathak RR; Clayman E; Xue B; Uversky VN; Davé V
    Mol Biosyst; 2014 Nov; 10(11):2876-88. PubMed ID: 25099472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy.
    Cheng F; Jia P; Wang Q; Zhao Z
    Oncotarget; 2014 Jun; 5(11):3697-710. PubMed ID: 25003367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cinnamic Acid Derivatives as Inhibitors of Oncogenic Protein Kinases--Structure, Mechanisms and Biomedical Effects.
    Mielecki M; Lesyng B
    Curr Med Chem; 2016; 23(10):954-82. PubMed ID: 26980568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive review of protein kinase inhibitors for cancer therapy.
    Kannaiyan R; Mahadevan D
    Expert Rev Anticancer Ther; 2018 Dec; 18(12):1249-1270. PubMed ID: 30259761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors.
    Verkhivker GM
    Curr Med Chem; 2017; 24(42):4838-4872. PubMed ID: 27719654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Landscape of Atypical and Eukaryotic Protein Kinases.
    Kanev GK; de Graaf C; de Esch IJP; Leurs R; Würdinger T; Westerman BA; Kooistra AJ
    Trends Pharmacol Sci; 2019 Nov; 40(11):818-832. PubMed ID: 31677919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Clinical Kinase Index: A Method to Prioritize Understudied Kinases as Drug Targets for the Treatment of Cancer.
    Essegian D; Khurana R; Stathias V; Schürer SC
    Cell Rep Med; 2020 Oct; 1(7):100128. PubMed ID: 33205077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities.
    Ghith A; Ismail NSM; Youssef K; Abouzid KAM
    Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 29027246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.